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Abstract
Background: Severe infections may lead to chronic inflammation in the central nervous system (CNS) which may in turn
play a role in the etiopathogenesis of amyotrophic lateral sclerosis (ALS). The relentless progression and invasive supportive
treatments of ALS may on the other hand induce severe infections among ALS patients.
Methodology and Principal Findings: The present study included 4,004 ALS patients identified from the Swedish Patient
Register during 1991–2007 and 20,020 age and sex matched general population controls. Conditional logistic regression
was used to estimate the odds ratios (ORs) of ALS given a previous hospitalization for CNS infection or sepsis. Cox models
were used to estimate the hazard ratios (HRs) of hospitalization for CNS infection or sepsis after ALS diagnosis. Overall,
previous CNS infection (OR: 1.3, 95% confidence interval [CI]: 0.8, 2.4) or sepsis (OR: 1.2, 95% CI: 0.9, 1.6) was not associated
with ALS risk. However, compared to ALS free individuals, ALS cases were more likely to be hospitalized for sepsis after
diagnosis (HR: 2.6, 95% CI: 1.9, 3.5). We did not observe a higher risk of CNS infection after ALS diagnosis.
Conclusions/Significance: Our results suggest that acute and severe infections unlikely contribute to the development of
ALS; however, ALS patients are at a higher risk of sepsis after diagnosis, compared to ALS free individuals.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative
disease mainly affecting motor neurons. About 5–10% of ALS
patients have a familial origin and the rest are sporadic cases.
Twin studies suggest a heritability of sporadic ALS of 0.61 with the
unshared environmental component as 0.39 [1]. Genes found
mutated in familial ALS have also been seen in sporadic ALS [2].
It is statistically possible that rare variants could account for the
genetic component of apparently sporadic cases [3]. Environmen-
tal exposures remain important either by contributing to ALS risk
independently or by interacting with genetic variations.
A chronic inflammatory process in the central nervous system
(CNS) has repeatedly been suggested as a pathophysiological
component in the disease [4] and the potential utility of anti-
inflammatory therapy has attracted much research interest [5,6].
A less well addressed question is however the origins of
neuroinflammation. One possibility is mutant superoxide dismu-
tase 1 (SOD1) which may activate microglia and damage neurons
and thus induce a vicious cycle of inflammation in the CNS [7].
However, SOD1 mutations are present in only 20% of the familial
ALS cases and are rare in sporadic cases, so other sources of
neuroinflammation may also be important.
Acute immune responses to severe infections may also initiate
sustained chronic inflammatory processes in the CNS. In animal
experiments, both intracerebral and intraperitoneal challenges by
lipopolysaccharide (LPS) induce sustained inflammations in the
CNS and subsequent neuron death [8]. In addition, viral
infections have long been suspected as potential contributors to
ALS pathogenesis [9,10]. For example, enteroviral components
accompanied by the infiltration of peripheral immune cells have
been found in the CNS of sporadic ALS cases [11,12]. However,
to the best of our knowledge, no epidemiological study has been
conducted to evaluate the role of severe infections in relation to
ALS risk. Using the Swedish Patient Register which has
independently collected hospital records for infections and ALS,
we tested the hypothesis that previous CNS infection or sepsis
might increase the future risk of ALS.
Severe infections may also be a consequence of ALS, due to the
deteriorating overall health condition of the patients and
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examination of death certificates, previous studies often showed
that complications with respiratory infections at the terminal stages
of ALS are common [13,14,15,16,17,18]. However, there are little
data on other infections after ALS diagnosis. We therefore further
tested the hypothesis that ALS patients were more likely to be
hospitalized for CNS infection or sepsis compared to individuals
free of ALS.
Materials and Methods
Ethics Statement
The study was approved by the Regional Ethical Vetting Board
in Stockholm, Sweden, who waived the need for consent as we
only analyzed de-identified data.
Swedish Patient Register
Since 1964–1965, the Swedish National Board of Health and
Welfare has compiled data on individual hospital discharge
diagnoses coded according to the International Classification of
Diseases (ICD) (ICD-7 before 1969, ICD-8 for 1969–1986, ICD-
9 for 1987–1996, and ICD-10 for 1997 and onward). This
Inpatient Register (IPR) started in a few counties and became
nationwide in 1987. The Outpatient Register (OPR) was
established in 2001, covering outpatient visits to specialist care.
Both the IPR and the OPR (referred to collectively as the Patient
Register) record one primary diagnosis and up to eight secondary
diagnoses for each clinic visit, along with information on the dates
of contact and discharge.
We identified ALS cases from both the IPR and the OPR.
Figure 1 illustrates the annual number of the IPR cases during
1991–2007 and the additional cases identified from the OPR
during 2001–2007, in the entire country. The majority of the ALS
cases (87%) could be identified from the IPR. More additional
cases were seen in 2001 and during 2006–2007 from the OPR, the
former probably due to the inclusion of prevalent cases at the
beginning of the OPR and the latter likely due to newly diagnosed
cases not yet hospitalized.
Nested case-control study – previous infections and ALS
risk
We conducted a nested case-control study within the population
of all individuals that were born in Sweden during 1901–1970 and
included in the Swedish Population and Household Survey in
1990. The National Registration Number (NRN), a unique
identifier for each resident in Sweden, enables unambiguous
linkage across various health and population registers held by the
Swedish National Board of Health and Welfare and the Statistics
Sweden. Via the unique NRN, the whole study population was
followed between January 1
st 1991 and December 31
st 2007
through linkages to the Swedish Patient, Causes of Death, and
Emigration Registers.
Cases were defined as individuals with a first-ever identifiable
inpatient or outpatient visit where ALS was recorded as either the
primary or a secondary diagnosis in the Patient Register (1991–
1996 ICD-9 code: 335C and 1997–2007 ICD-10 code: G12.2).
The date of the first hospital visit was defined as the diagnosis date
for ALS. Individuals that had died, emigrated out of Sweden or
been hospitalized for ALS before January 1
st 1991 were excluded
from the cohort. Follow-up was censored at ALS diagnosis,
emigration out of Sweden, or death, whichever occurred first. A
total of 4,004 ALS patients were identified during the study period,
the majority (91%) with ALS as the primary diagnosis. Before
2001, cases could only be identified from the IPR (n=1,938).
Between 2001 and 2007, there were 2,066 cases including 393
cases (19%) that were identifiable only in the IPR, 483 (23%) only
in the OPR, and 1,190 (58%) in both the IPR and the OPR.
Among the latter cases, 390 (33%) were first recorded in the IPR
and later in the OPR and 800 (67%) vice versa. The median
interval between the first OPR record and the first IPR record for
Figure 1. Number of amyotrophic lateral sclerosis patients identified in the Inpatient and Outpatient Registers in Sweden during
1991–2007.
doi:10.1371/journal.pone.0029749.g001
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serves as the real diagnosis date of ALS, the delay of the IPR
identification is likely to be no more than a few months.
Using incidence density sampling, we randomly selected 20,020
controls (five per case) from the entire study population that were
individually matched to the ALS cases on age and sex. Eligible
controls were persons that were alive and free of ALS on the
diagnosis date of the case they were matched to (i.e., index date).
With this nested case-control design, we estimated a statistical
power of .80% for detecting an odds ratio (OR) of 1.6, assuming
1% of infection among controls and an a of 0.05.
Our exposure of interest was hospitalization due to CNS
infection or sepsis identified from the IPR. To ensure a complete
identification of such hospitalizations, we defined the exposure
status of the cases and controls between January 1
st 1987, when
the IPR achieved nationwide coverage, and the index date. We
used ICD codes for CNS infection and sepsis according to a
previously published study which compared the records of
infections in the Swedish Patient Register with medical records
from the intensive care units [19]. Briefly, CNS infections were
defined as ICD-9 codes 006F, 013, 036A, 036B, 045–049, 052B,
053A, 053B, 054D, 054H, 055A, 056A, 062–064, 072B, 072C,
094, 136C, and 320–325, and ICD-10 codes A06.6, A17, A39,
A80–A89, B00.3, B00.4, B01.0, B01.1, B02.0, B02.1, B05.0,
B05.1, B06.0, B22.0, B26.1, B26.2, B37.5, B38.4, B43.1, B50.0,
B58.2, B60.2, G00–G08, and R29.1. For sepsis, we used the
narrow criteria of sepsis as described in the same paper with ICD-
9 codes 036C-036E, 036X, 038, 084, 112F, 117D, 286G, and
999D, and ICD-10 codes A02.1, A04.0-A04.3, A39–A41, A42.7,
A48, A90–A99, B37.7, B38.7, B39.3, B40.7, B41.7, B42.7, B44.7,
B45.7, B46.4, B95–B99, D65, and T80.2. The codes for CNS
infections had a sensitivity of 84.0% and specificity of 99.7% while
the codes for sepsis had a lower sensitivity (,43%) but still a high
specificity (,97%) [19].
Follow-up of ALS cases and controls – infections after
ALS
To examine the relative risk of hospitalizations for CNS
infection or sepsis after ALS diagnosis, we prospectively followed
the cases and controls from the index date to death, emigration out
of Sweden or December 31
st 2007, whichever came first.
Statistical analysis
To evaluate the association of previous hospitalizations for
CNS infection or sepsis with a later ALS occurrence, we derived
ORs and corresponding 95% confidence intervals (CIs) from
conditional logistic regression models. The exposure was first
defined as an ever hospitalization for CNS infection or sepsis
from January 1
st 1987 to the index date, and then categorized
according to the time interval between such hospitalizations and
ALS diagnosis as sample size allowed: ,3 years and $3 years for
CNS infection and ,1 year, 1 to 3 years, and $3 years for sepsis.
These analyses were conducted to explore the temporal
relationship between exposures and outcome. In case of multiple
hospitalizations, the first event was used in the primary analysis.
Consecutive transfers among different clinics were counted as one
hospitalization. We also examined the importance for ALS risk of
number of hospitalizations (once or more than once) at least 3
years before the index date, assuming a 3-year induction time for
ALS.
In addition to the main analysis we conducted parallel analyses
restricted to cases first identified in the OPR, assuming that the
first OPR record was the real date of diagnosis of ALS. Since some
prevalent cases might have been included in the OPR during 2001
when it was started, we further restricted these analyses to
individuals first included in the OPR in 2002–2007 (termed
‘‘incident cases’’, n=1,050).
The follow-up of ALS patients and controls after the index date
identified no case but 35 controls that were hospitalized for CNS
infection and therefore the analysis of ALS with later hospitaliza-
tions for infections was only conducted for sepsis. Hazard ratios
(HRs) and 95% CIs were derived from Cox proportional hazards
models. To illustrate the importance of the immediate period after
diagnosis, we further stratified the analyses by time since index
date, i.e., first year after index date and .1 year after index date.
All statistical analyses were performed with SAS 9.1 (SAS
Institute, North Carolina, USA) and the significance tests were
two-tailed with a=0.05.
Results
Incident cases were about 3 years younger on average
(P,0.001) compared to other cases (Table 1). On average, cases
with previous CNS infection were the same age as cases without
previous CNS infection; whereas cases with previous sepsis were
older than cases without previous sepsis (P=0.006), especially if
sepsis happened ,3 years before ALS diagnosis (Table 1). Cases
with sepsis before diagnosis were more likely to be male (P=0.007;
x
2 test).
Overall, there was no association between ALS occurrence and
previous hospitalization for either CNS infection (OR: 1.3, 95%
CI: 0.8, 2.4) or sepsis (OR: 1.2, 95% CI: 0.9, 1.6) (Table 2).
However, cases were more likely to be hospitalized for sepsis in the
year preceding diagnosis compared to controls (OR: 2.6, 95% CI:
1.6, 4.2). This observation did not persist when the analysis was
restricted to incident cases (OR: 1.0, 95% CI: 0.3, 2.9).
Occurrence of multiple hospitalizations for either CNS infection
or sepsis $3 years before the index date was not associated with a
higher risk of ALS, but the estimates are based on small numbers
(Table 2). To further examine the temporal relationship between
infections and ALS, we evaluated separately associations of ALS
with infections occurring $3t o,10 years previously and $10
Table 1. Basic characteristics of amyotrophic lateral sclerosis
cases, a nested case-control study in Sweden, 1991–2007.
Groups No.
Mean age at
diagnosis
(SD), years Men (%)
All cases 4,004 68.8 (11.5) 2,242 (56.0)
Incident cases
* 1,050 66.6 (11.5) 606 (57.7)
Other cases 2,954 69.5 (11.4) 1,636 (55.4)
Previous infection of the central nervous system
No 3,989 68.8 (11.5) 2,232 (56.0)
Yes 15 68.7 (13.2) 10 (66.7)
,3 yrs before index date 5 72.2 (16.5) 4 (80.0)
$3 yrs before index date 10 67.0 (11.9) 6 (60.0)
Previous sepsis
No 3,935 68.7 (11.5) 2,192 (55.7)
Yes 69 72.6 (10.9) 50 (72.5)
,3 yrs before index date 43 74.3 (9.5) 30 (69.8)
$3 yrs before index date 26 69.6 (12.6) 20 (76.9)
*Cases first recorded in the Outpatient Register during 2002–2007.
doi:10.1371/journal.pone.0029749.t001
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0.8, 3.9) for CNS infection and 0.7 (95% CI: 0.5, 1.2) for sepsis;
ORs for the latter period were 0.6 (95% CI: 0.1, 2.7) for CNS
infection and 0.9 (95% CI: 0.4, 2.1) for sepsis.
Among cases, 71 (incidence rate: 11.4/1000 person-years) were
hospitalized for sepsis at least once after the index date, with the
first hospitalization for sepsis occurring on average 26 months
later. The corresponding numbers for controls were 803 (incidence
rate: 6.6/1000 person-years) and 65 months respectively. Overall,
ALS cases were more likely than controls to be hospitalized for
sepsis during the follow-up (HR: 2.6, 95% CI: 1.9, 3.5). During the
first year after the index date, 85 controls and 29 cases were
hospitalized for sepsis with an HR of 3.0 (95% CI: 1.9, 4.8) while
comparing cases to controls (Table 3). Similar results were
obtained after restricting the analyses to incident cases and their
controls.
Discussion
This is the first large epidemiological study to examine the
interrelationship of CNS infection or sepsis with ALS. We found
little evidence that prior CNS infection or sepsis increases the
future risk of ALS occurrence. However, our data suggest that
Table 2. Previous hospitalizations for infection of the central nervous system (CNS) or sepsis and the risk of amyotrophic lateral
sclerosis, a nested case-control study in Sweden, 1991–2007.
Groups All cases and controls (N=24,024) Incident cases and controls (N=6,300)
{
Controls Cases OR (95% CI)
* Controls Cases OR (95% CI)
*
Previous CNS infections
No 19,964 3,989 1.0 5,230 1,048 1.0
Yes 56 15 1.3 (0.8–2.4) 20 2 0.5 (0.1–2.1)
Years before index date
,3 17 5 1.5 (0.5–4.0) 4 0 -
$3 39 10 1.3 (0.6–2.6) 16 2 0.6 (0.1–2.7)
No. of infections $3 years before index date
1 34 9 1.3 (0.6–2.8) 13 2 0.8 (0.2–3.4)
.1 5 1 1.0 (0.1–8.6) 3 0 -
Previous sepsis
No 19,728 3,935 1.0 5,145 1,035 1.0
Yes 292 69 1.2 (0.9–1.6) 105 15 0.7 (0.4–1.2)
Years before index date
,1 52 27 2.6 (1.6–4.2) 20 4 1.0 (0.3–2.9)
1,3 71 16 1.1 (0.7–2.0) 23 5 1.1 (0.4–2.8)
$3 169 26 0.8 (0.5–1.2) 62 6 0.5 (0.2–1.1)
No. of infections $3 years before index date
1 155 24 0.8 (0.5–1.2) 55 5 0.4 (0.2–1.1)
.1 14 2 0.7 (0.2–3.2) 7 1 0.7 (0.1–5.8)
*Odds ratios and 95% confidence intervals, adjusting for year of birth and sex.
{Cases first recorded in the Outpatient Register during 2002–2007.
doi:10.1371/journal.pone.0029749.t002
Table 3. Hazard ratios of hospitalization for sepsis after amyotrophic lateral sclerosis, a follow-up study in Sweden, 1991–2007.
Groups All cases and controls (N=24,024) Incident cases and controls (N=6,300)
{
No. hospitalized
for sepsis Person-years HR (95% CI)
*
No. hospitalized
for sepsis Person-years HR (95% CI)
*
First year after index date
Controls 85 19,046 1.0 24 4,740 1.0
Cases 29 2,541 3.0 (1.9–4.8) 10 812 3.0 (1.4–6.7)
.1 year after index date
Controls 730 102,745 1.0 79 10,297 1.0
Cases 43 3,690 2.3 (1.6–3.4) 9 926 1.6 (0.8–3.5)
*Hazard ratios and 95% confidence intervals, adjusting for year of birth and sex.
{Cases first recorded in the Outpatient Register during 2002–2007.
doi:10.1371/journal.pone.0029749.t003
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individuals without ALS.
The strengths of the present study include the large number of
ALS cases and controls, independently and prospectively collected
data on infections and ALS, and the complete follow-up.
However, even using these large national registers, many analyses
were still based on small numbers due to the rarity of both the
exposures and outcome. Another potential limitation is that ALS
cases were identified from the Patient Register and, before 2001,
solely from the IPR. It is therefore likely that we missed cases who
had not been hospitalized either specifically for ALS or for other
reasons. However, inclusion of patients from the OPR after 2001
should allow us to capture most of, if not all, cases since ALS
patients often need to visit a specialist for a definitive diagnosis and
treatment. Furthermore, the fact that IPR patients were
hospitalized with a mean of 5 months after first OPR identification
suggests that even the IPR might have identified ALS cases in a
timely manner. As cases were identified from the registers, we did
not have detailed data on ALS diagnosis and clinical features, such
as the date and site of onset. Finally, although no specific
validation has been conducted for ALS diagnosis in the Patient
Register, clinical diagnosis of ALS is believed to be accurate and
correlates well with post-mortem diagnosis [18] and the general
quality of diagnoses in the IPR has been shown to be high [20].
We have observed a high agreement between the IPR and the
OPR in the present study as well as between the IPR and the
Causes of Death Register previously [21].
A disturbed homeostasis of microglia and a transformation of
microglia from resting to reactivated status is a prominent feature
of ALS pathology [6]. The initial function of microglia is to
maintain the homeostatic balance of the microenvironment in the
CNS, and this ‘‘surveillance’’ task is usually accomplished while
facing mild insults. Strong insults to the CNS, such as infectious
challenges or significant brain injuries, may incur excessive
microglia activation and inflammatory responses. These inflam-
matory responses may persist after the acute insult, eventually
turning into a self-perpetuating hazardous cycle, and thus
contribute to neuronal damage [22,23]. In the present study, we
studied hospitalizations for sepsis or CNS infection as proxies for
severe systemic and CNS infections that are more likely to have
long-term neurological consequences than mild peripheral infec-
tions. Sepsis is a systemic inflammatory syndrome in response to
infections. In contrast to our expectations, neither CNS infection
nor sepsis was associated with higher ALS occurrence. The
positive association observed between sepsis during the year before
index date and ALS may most likely be due to reverse causality
given that ALS patients appear more prone to sepsis than controls.
In support of this suggestion, we did not observe a higher ALS risk
associated with sepsis among incident cases, while we did find a
higher sepsis risk among ALS cases after diagnosis.
One possible explanation for our finding of no association
betweensevereinfectionsand ALSriskmaybethatsevereinfections
influence disease progression rather than initiation. In experimental
models, intracerebral or intraperitoneal injection of LPS leads to an
exacerbated neuroinflammation during chronic neurodegeneration
[8], whereas intraparenchymal injection of LPS in the normal brain
provokes only limited inflammatory response [24]. This suggests
that the influencesofsuchchallengesmightbemore pronounced for
ALS progression, when neurodegeneration is already ongoing,
compared to ALS onset. This line of reasoning is consistent with the
finding in a mouse model that selective mutation of SOD1 in motor
neuronsbutnotgliadeterminestheonset ofALSwhilethemutation
confined to microglial cells influences the progression of ALS after
disease onset[25,26]. Similarly, although few studies haveevaluated
the impact of infection on Alzheimer’s disease risk, some
epidemiological and clinical studies have shown that infections
accelerate the progression of Alzheimer’s disease [27,28]. There-
fore, future investigations of the association between severe
infectionsandALSsurvival,independent ofotherknown prognostic
indicators, are warranted.
Another potential explanation for our null finding is that the
infections of the exposed individuals were likely well controlled after
hospitalization, making the exposure a severe but transient event.
Antibiotic treatment given to mice with systemic infections sufficiently
controls neuroinflammation, seemingly explaining the null effect of
recurrent systemic infectious challenges on ALS onset and progres-
sion in this model [29]. A transient infection, however severe, might
not be enough to initiate neurodegeneration, whereas a sustained
long term chronic infection might have a stronger diseasemodulating
influence. Studies able to collect information on more chronic
infections, such as septic arthritis, should be considered.
It is known that ALS patients often die of infectious
complications in the respiratory system, possibly secondary to
ventilatory failure caused by respiratory muscle weakness in the
terminal stages of ALS [13,14,15,16,17,18]. The overall deterio-
rating condition of ALS patients, such as malnutrition, in addition
to respiratory failure, might put ALS patients at a higher risk of
severe infections including sepsis. Furthermore, ALS patients may
undergo significantly invasive treatments including tracheostomy
or percutaneous endoscopic gastrostomy placement which could
potentially also lead to an increased risk of sepsis. Despite the
rareness of sepsis, our data suggest that it is a severe complication
for ALS patients after diagnosis. This may have clinical
implications for health professionals and caregivers of ALS
patients. On the other hand, we observed no cases but 35 controls
that were hospitalized for CNS infection after the index date,
making analyses on CNS infection after ALS diagnosis impossible.
This observation is however not surprising. Assuming a similar
hospitalization rate of CNS infection between the cases and
controls, the expected number of ALS cases hospitalized for CNS
infection after diagnosis is only 1.8.
In conclusion, our study did not support a positive association
between previous hospitalization for CNS infection or sepsis and
an increased risk of ALS. Future studies should address whether
these conditions are related to ALS prognosis. ALS patients are at
a higher risk of sepsis after diagnosis and this should be taken into
consideration in the clinical care of ALS.
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